Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study

Background: Crizanlizumab is a novel inhibitor of P-selectin, a key player in multicellular adhesion and inflammatory signaling, that leads to vaso-occlusion in sickle cell disease (SCD). Objectives: The SOLACE-adults study evaluated the pharmacokinetics, pharmacodynamics (P-selectin inhibition), sa...

Descrición completa

Detalles Bibliográficos

Principais autores:	Julie Kanter, Sarah Mennito, Santosh M. Nair, Deepa Manwani, Abdullah Kutlar, Nirmish Shah, Deborah Keefe, Hariprasad Madhamshetty, Michele Nassin, Evgeniya Reshetnyak, Anisha E. Mendonza, Darla Liles
Formato:	Artigo
Idioma:	Inglês
Publicado:	SAGE Publishing 2024-11-01
Series:	Therapeutic Advances in Hematology
Acceso en liña:	https://doi.org/10.1177/20406207241292508
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!